Optibrium Raises Investment to Advance Computer-Aided Drug Discovery

Optibrium™, a developer of software for drug discovery, today announced it has raised significant investment from Kester Capital, a leading UK mid-market private equity firm typically investing between £10 to £20 million per deal.

The funding will accelerate the development of the business through organic growth and acquisition. Currently, more than 150 organizations worldwide deploy Optibrium’s technology in their research programs, including five of the top ten global pharmaceutical companies.

Founded in 2009 by Matt Segall, CEO, and Ed Champness, Chief Scientific Officer, Optibrium is based in Cambridge, UK with offices in the USA in Boston and San Francisco. Optibrium’s products enable preclinical drug discovery, focusing on ‘hit to lead’ and ‘lead optimization’ phases. Their lead products are StarDrop™ and Cerella™.

StarDrop is a comprehensive suite of integrated software for small molecule design, optimization, and data analysis that enhances the drug discovery process’s speed and productivity. The Cerella™ platform delivers a groundbreaking and proven artificial intelligence technology that learns from complex drug discovery data to target high-potential chemical compounds.

The market for computer-aided drug discovery (CADD) is fast-growing, driven by the increasing capabilities and sophistication of software tools that can deliver material cost and time savings for drug developers. Independent market research[1] predicts that the global CADD market will surpass $4.8 billion by 2026, rising from $1.5 billion in 2018 at a CAGR of 15.5%.

Adam Maidment, the managing partner of Kester Capital, said: “Optibrium is a cutting edge software business that is driving some of the most exciting developments within computer-aided drug discovery. We had been tracking the business for some time and were really impressed by the team and the business’ achievements. We are looking forward to working with Matt and Ed to grow the business.”

We are delighted to have Kester Capital on board as an investment partner to continue the successful evolution of the business. Kester has extensive experience in the life sciences sector, and we are looking forward to working with them to capitalize on the substantial market opportunities.”

Matt Segall, CEO of Optibrium

For further information on Optibrium, StarDrop, or Cerella, please visit www.optibrium.com, contact [email protected] or call +44 1223 815900.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2023, March 08). Optibrium Raises Investment to Advance Computer-Aided Drug Discovery. News-Medical. Retrieved on May 19, 2024 from https://www.news-medical.net/news/20210210/Optibrium-Raises-Investment-to-Advance-Computer-Aided-Drug-Discovery.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium Raises Investment to Advance Computer-Aided Drug Discovery". News-Medical. 19 May 2024. <https://www.news-medical.net/news/20210210/Optibrium-Raises-Investment-to-Advance-Computer-Aided-Drug-Discovery.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium Raises Investment to Advance Computer-Aided Drug Discovery". News-Medical. https://www.news-medical.net/news/20210210/Optibrium-Raises-Investment-to-Advance-Computer-Aided-Drug-Discovery.aspx. (accessed May 19, 2024).

  • Harvard

    Optibrium Ltd.. 2023. Optibrium Raises Investment to Advance Computer-Aided Drug Discovery. News-Medical, viewed 19 May 2024, https://www.news-medical.net/news/20210210/Optibrium-Raises-Investment-to-Advance-Computer-Aided-Drug-Discovery.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Optibrium appoints computational modelling expert, Dr Hamed Tabatabaei Ghomi as Head of Research